Cargando…

HBV Infection in HIV-Driven Immune Suppression

Worldwide, approximately 10% of all human immunodeficiency virus (HIV)-infected people are also chronically coinfected with hepatitis B virus (HBV). HBV infection has a poor prognosis in HIV-positive people and has been documented by an increased risk of developing chronic HBV infection (CHB), progr...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarmati, Loredana, Malagnino, Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893694/
https://www.ncbi.nlm.nih.gov/pubmed/31752284
http://dx.doi.org/10.3390/v11111077
_version_ 1783476258906046464
author Sarmati, Loredana
Malagnino, Vincenzo
author_facet Sarmati, Loredana
Malagnino, Vincenzo
author_sort Sarmati, Loredana
collection PubMed
description Worldwide, approximately 10% of all human immunodeficiency virus (HIV)-infected people are also chronically coinfected with hepatitis B virus (HBV). HBV infection has a poor prognosis in HIV-positive people and has been documented by an increased risk of developing chronic HBV infection (CHB), progression to liver fibrosis and end-stage liver disease (ESLD) and evolution of hepatocellular carcinoma (HCC). Furthermore, in HIV patients, HBV-resolved infection is often associated with the appearance of HBV-DNA, which configures occult HBV infection (OBI) as a condition to be explored in coinfected patients. In this narrative review we summarize the main aspects of HBV infection in HIV-positive patients, emphasizing the importance of carefully considering the coinfected patient in the context of therapeutic strategies of antiretroviral therapy.
format Online
Article
Text
id pubmed-6893694
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68936942019-12-23 HBV Infection in HIV-Driven Immune Suppression Sarmati, Loredana Malagnino, Vincenzo Viruses Review Worldwide, approximately 10% of all human immunodeficiency virus (HIV)-infected people are also chronically coinfected with hepatitis B virus (HBV). HBV infection has a poor prognosis in HIV-positive people and has been documented by an increased risk of developing chronic HBV infection (CHB), progression to liver fibrosis and end-stage liver disease (ESLD) and evolution of hepatocellular carcinoma (HCC). Furthermore, in HIV patients, HBV-resolved infection is often associated with the appearance of HBV-DNA, which configures occult HBV infection (OBI) as a condition to be explored in coinfected patients. In this narrative review we summarize the main aspects of HBV infection in HIV-positive patients, emphasizing the importance of carefully considering the coinfected patient in the context of therapeutic strategies of antiretroviral therapy. MDPI 2019-11-19 /pmc/articles/PMC6893694/ /pubmed/31752284 http://dx.doi.org/10.3390/v11111077 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Sarmati, Loredana
Malagnino, Vincenzo
HBV Infection in HIV-Driven Immune Suppression
title HBV Infection in HIV-Driven Immune Suppression
title_full HBV Infection in HIV-Driven Immune Suppression
title_fullStr HBV Infection in HIV-Driven Immune Suppression
title_full_unstemmed HBV Infection in HIV-Driven Immune Suppression
title_short HBV Infection in HIV-Driven Immune Suppression
title_sort hbv infection in hiv-driven immune suppression
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893694/
https://www.ncbi.nlm.nih.gov/pubmed/31752284
http://dx.doi.org/10.3390/v11111077
work_keys_str_mv AT sarmatiloredana hbvinfectioninhivdrivenimmunesuppression
AT malagninovincenzo hbvinfectioninhivdrivenimmunesuppression